RecruitingNCT06541132

Positive Association of US-FLI With the Severity of CAD

Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease


Sponsor

Chongqing Medical University

Enrollment

190 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria2

  • Patients older than 18 years old
  • Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study

Exclusion Criteria7

  • Incomplete clinical data
  • previous coronary stent implantation
  • no abdominal ultrasound examination
  • poor ultrasound image quality
  • congenital heart disease
  • tumor
  • thyroid diseases and infectious diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational study without human intervention

Observational study without human intervention


Locations(1)

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06541132


Related Trials